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An imperfect “PAST” Lessons learned




Asthma deaths are a barometer of the quality of asthma care. The principal care for patients with severe asthma is often
a joint partnership between primary and secondary services. Communication between the two services determines the
effectiveness of treatment. Undertaking an audit on asthma in either primary or separately in secondary care is a
relatively straightforward process. However, when the audit spans both primary and secondary care in a country as
large as the United Kingdom which is further sub-divided into the separate healthcare systems of England, Wales,
Scotland, and Northern Island, then the audit becomes considerably more challenging. The National Review of Asthma
Deaths (NRAD) reported in May 2014 was a confidential enquiry tasked with identifying circumstances surrounding
asthma deaths across the whole of the UK, in order to ascertain avoidable factors and make recommendations to
improve care and reduce future asthma deaths (Why asthma still kills: the National Review of Asthma Deaths (NRAD)
Confidential Enquiry report, 2014, http://www.rcplondon.ac.uk/sites/default/files/why-asthma-still-kills-full-report.pdf). The
idea for NRAD arose from a longstanding East of England confidential enquiry started in 1988 by Dr Brian Harrison and
then handed onto me in 2001 until funding for the national review of asthma deaths was secured in 2010.
Abbreviations: ED, Emergency department; LABA, long acting beta agonist; NRAD, National review of asthma deaths;
NSAID, non-steroidal anti-inflammatory drugs; PAAP, personal asthma action plans; SABA, short-acting beta-agonist
In the UK one in eight or 5.4 million of the population
receives treatment for asthma with 65,000 hospital ad-
missions each year representing one of the highest
prevalence rates for asthma in the world. The number of
deaths has plateaued at approximately 1,200 deaths per
year with a gradual trend for reduced asthma mortality
in recent years. The East of England Confidential
Enquiry on which NRAD [1] was modelled had
highlighted that the majority of asthma deaths were pre-
ventable with triggers in the young distinct to those
found in an older population [2, 3]. Previous confidential
enquiries had also reported that many asthma deaths oc-
curred in patients who did not have a history of severe
asthma. Earlier audits had commented on preventable
factors but these had focussed mainly to psychosocial
factors contributing to poor compliance and sub-optimal
attendance at hospital and primary care appointments
[4]. Other audits had highlighted that the fatal asthma
attack was often of sudden onset [5, 6] which may have
been responsible for the delay in calling for help. A sig-
nificant proportion of patients had been hospitalised in
the year before death suggesting on-going poor control
but also highlighting opportunities for intervention and
prevention of death [6, 7]. There was concern about
underuse of objective recordings and delay in the use of
mechanical ventilation [7]. One audit reporting on
asthma deaths had usefully identified the relationship
between peak flow variability and risk of death [8]. Some
studies highlighted the issue of overuse of bronchodila-
tor therapies in patients with poorly controlled asthma
who subsequently died [9]. Many of these reports rec-
ommended better treatment of the final attack before
death and suggested methods for improving compliance
with therapy. The East of England Confidential Enquiry
however did not view each asthma death as a single
missed opportunity, rather as a series of failed opportun-
ities principally because of a lack of individual asthma
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phenotyping. The lack of understanding of an individual’s
underlying asthma mechanism results in triggers
remaining unidentified and patients are therefore unable
to anticipate and prevent exacerbations. Ineffective man-
agement can lead to mistrust of healthcare, a breakdown
of communication and ultimately hampers compliance.
Asthma deaths occurring in the 12 months between
February 2012 and January 2013 were identified from
government statistic agencies. Asthma deaths recorded
on the death certificate and coded as the underlying
cause of death were included. More stringent criteria
were used in those patients aged over 75 due to co-
morbidities contributing to death. Using these criteria
900 deaths were identified. Further screening excluded
those that did not have asthma or asthma was very un-
likely to have contributed to death. In some cases insuf-
ficient information was available for a detailed review or
clinicians refused to provide information. Eventually 195
cases were identified as having died from asthma and a
detailed examination of their medical history was under-
taken from primary and secondary care records. The re-
view panel comprised 174 volunteer clinical assessors
made up of paediatricians, adult physicians, general
practitioners, pharmacists, and nurses with an interest in
respiratory medicine.
Key findings
The median age at the time of initial diagnosis of asthma
was 37 years in the 195 deaths, and 69 % were diagnosed
with asthma after the age of 15 years (Table 1). A number
of avoidable factors were related to patients themselves, or
their environment including non-adherence to medical ad-
vice and tobacco smoking or exposure to second hand
smoke in the home. The expert clinical assessors identified
that 46 % of the deaths could be prevented with alternative
management if clinicians had better knowledge and imple-
mented asthma guidelines. Psychosocial factors have been
seen as an important contributor of asthma deaths and
16 % of asthma deaths had mental health issues for ex-
ample anxiety and depression, social isolation was seen in
7 % and problems with substance abuse recorded in 6 %.
Previous asthma severity
Forty five per cent died without seeking medical help
and only 31 % made it to hospital before death (Fig. 1).
Only 43 % of the people who died from asthma had been
under specialist supervision in the 12 months prior to
death. Fewer than half had a history of previous hospital
admission for asthma, although 10 % died within 28 days
of discharge from hospital after treatment for asthma.
21 % had attended a hospital Emergency Department
(ED) in the year before death and 10 % on more than
one occasion. Of the 125 patients for whom severity
could be estimated, only 39 % appeared to have severe
asthma and 9 % were being treated for mild asthma.
These statistics highlight that approximately half of the
people who die from asthma are known to specialist ser-
vices because of previous hospital admissions, ED visits,
or because they have a history of severe asthma requir-
ing specialist input. More surprising however are the
50 % of people who die from asthma who remain un-
detected either because they have a habit of avoiding
medical help during exacerbations, or they are poor at
recognising their own asthma symptoms, or they die
after their first asthma exacerbation. It is this group that
require the closest scrutiny, but often medical records








Fig. 1 Location of death
Table 1 Characteristics of NRAD patients who died from
asthma
Duration of asthma (n = 104) Median 11y (0-62y)
Age at diagnosis (n = 102) Median 37y (10 months – 90y)
Age at death (n = 193) Median 58 yrs (range 4 – 97 yrs)
Severity of asthma (n = 155) Mild 9 %-
Moderate- 49 %
Severe- 39 %
Previous asthma hospital admissions Hospital ever 47 %
Intensive care ever 15 %
Ventilation ever 7 %
Asthma triggers Recorded in 49 %
History of Allergy Recorded in 41 %
Evidence of eosinophilia Recorded in 15 %
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Taking treatment correctly
Personalised asthma action plans (PAAPs) are acknowl-
edged to improve asthma care but were provided for only
23 % confirming that PAAPs had not even been provided
for each of the 39 % considered to have severe asthma.
Approximately 40 % had been prescribed more than 12
short acting reliever inhalers in the year before death, and
a similar percentage had been issued with fewer than 4 in-
haled corticosteroid inhalers in the 12 months before
death. The proportion of overlap between these two
groups of patients was not known. 14 % of those who died
had been prescribed a single component long acting beta
agonist (LABA) at the time of death and at least 3 % were
taking a LABA without inhaled corticosteroid. This single
statistic lends considerable concern to the practice of pre-
scribing single device LABAs and inhaled corticosteroids
separately, as it allows the possibility of prescription errors
or confusion with treatment.
Recommendations
NRAD concluded that a significant number of asthma
deaths can be averted with implementation of the fol-
lowing small number of key recommendations.
Asthma phenotype
The common misconception that an individual’s asthma
phenotype or triggers are unimportant continues to be
propagated in clinical practice despite international guide-
lines [10]. Exacerbating factors or triggers were docu-
mented in only half the patients. There was a possible
history of atopy in 50 % and at least 15 % had evidence of
eosinophilia on blood count. Until phenotyping becomes
routine it is unlikely that asthma care will improve or
deaths reduced significantly. All patients diagnosed with
asthma should undergo clinical phenotyping in order to
identify likely triggers, and these include pollens and fun-
gal spores in those with predominantly sudden-onset at-
tacks or seasonal symptoms especially in atopic subjects
under the age of 45y [11, 12]. In older subjects winter exac-
erbations starting after a respiratory tract infection or sinus-
itis are more common. Patients with predictable seasonal
exacerbations should undergo their annual asthma review a
month before their worst season (Table 2).
Self-management
Each patient with asthma should have a written and per-
sonalised asthma action plan recording their likely
phenotype (e.g. allergic, non-allergic, eosinophilic, infect-
ive) and clinical triggers recorded. The plan should in-
clude details of current treatment and how to manage
exacerbations. The fact that only 50 % of those who died
from asthma called for help underscores the importance
of clear guidance on how to call for help within the
asthma action plan. Involvement of patients in their own
management should be encouraged and this is easier once
individual phenotypes have been identified and patients
informed of their identified triggers. Examples of ways to
encourage self-management include increasing medica-
tion before the start of the hay fever season, avoiding non-
steroidal anti-inflammatory drugs (NSAIDs) in susceptible
individuals, or the early use of oral corticosteroids with
viral- or allergen-induced exacerbations.
Follow-up and electronic surveillance
Patients frequently attending the Emergency Depart-
ment or those who have been recently discharged
from hospital should have timely follow up, and the
former group may require a degree of persuasion to
attend appointments. Every patient should have a
structured annual review of asthma control and treat-
ment with emphasis on preventing future exacerba-
tions. Where loss of control is identified, immediate
escalation of treatment is required and arrangements
made for follow up. An innovative NRAD recommen-
dation was electronic surveillance of inhaler prescrib-
ing in primary care in order to identify those patients
prescribed more than 12 short-acting beta-agonist
(SABA) or fewer than 4 corticosteroid inhaler devices
in the previous year. This allows the possibility of
preventative action in those demonstrating a lack of
understanding or poor compliance. The prescription
of long acting beta-agonists in a single device should
no longer be acceptable in asthma.
Table 2 Recommendations to reduce risk of asthma death
Risk Factor Recommendation
1. 45 % died at home without
calling for help and Personal
Asthma Action Plans (PAAPs)
had only been issued to 23 %
All patients with asthma to be
issued with PAAPs to include
• asthma triggers,
• current therapy,
• advice on treatment escalation and
• how to call for help
2. Failure to phenotype asthma
or identify triggers in >51 %
Asthma clinical phenotyping to
identify likely triggers and
underlying mechanism of asthma
3. No evidence of a review in
general practice in the last yr
for 43 %
Structured annual review of asthma
control preferably timed a month
before expected seasonal exacerbation
4. 10 % died within 28d of
hospital discharge and 21 %
died within 12mo of
attendance in ED
Follow-up arranged following every
attendance in ED and secondary
care follow-up after each hospital
admission for asthma
5. Excessive prescribing of SABA
(39 % issued with >12 devices
in previous 12mo) inadequate
uptake of ICS with 38 % issued
<4 devices in previous 12 mo
Electronic surveillance of inhaler
prescribing in primary care to identify
those prescribed >12 short-acting
beta-agonist or < 4 corticosteroid
inhaler devices in previous yr
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Remember “PAST”
The Eastern Region Confidential Enquiry into Asthma
Deaths coined the acronym “PAST” to reflect the key
measures required to reduce asthma deaths.
P = personalised asthma action plans
A = asthma phenotype
S = structured asthma review
T = therapy - avoiding:
 Excess SABAs,
 Non-combination LABAs, and
 Inadequate inhaled corticosteroids.
The future
An important question that NRAD failed to answer was
why do people die if they are considered to have mild to
moderate asthma? The study did not identify the indi-
vidual characteristics, phenotype, and behaviour patterns
of this group and therefore further study will be neces-
sary to understand whether this group are poorly com-
pliant, have specific triggers leading to sudden death, or
if they simply die following their first severe exacerba-
tion. Preventing future deaths will require a better un-
derstanding of this group in particular (Table 3).
Abbreviations
ED: emergency department; LABA: long acting beta agonist; NRAD: national
review of asthma deaths; NSAID: non-steroidal anti-inflammatory drugs;
PAAP: personal...ised (personalised) asthma action plans; SABA: short-acting
beta-agonist.
Funding
NRAD was commissioned and funded by the Healthcare Quality
Improvement Partnership on behalf of NHS England, NHS wales, the Health
and Social Care Division of the Scottish Government, and the Northern
Ireland Department of Health, Social Services and public health Safety.
Availability of data and materials
The full NRAD report is available from Why asthma still kills: the National
Review of Asthma Deaths (NRAD) Confidential Enquiry report. Royal College
of Physicians. London; 2014. Available from: http://www.rcplondon.ac.uk/
sites/default/files/why-asthma-still-kills-full-report.pdf
Competing interests
The authors declare that they have no competing interests.
Received: 25 February 2016 Accepted: 29 June 2016
References
1. Why asthma still kills: the National Review of Asthma Deaths (NRAD)
Confidential Enquiry report. Royal College of Physicians. London; 2014.
Available from: http://www.rcplondon.ac.uk/sites/default/files/why-asthma-
still-kills-full-report.pdf.
2. Harrison B, Stephenson P, Mohan G, Nasser S. An ongoing confidential
enquiry into asthma deaths in the Eastern Region of the UK, 2001–2003.
Prim Care Resp J. 2005;14:303–13.
3. Anagnostou K, Iles R, Harrison B, Nasser S. Risk factors for childhood asthma
deaths from the UK Eastern Region Confidential Enquiry 2001–6. Prim Care
Resp J. 2012.
4. Wareham NJ, Harrison BD, Jenkins PF, et al. A district confidential enquiry
into deaths due to asthma. Thorax. 1993;48:1117–20.
5. Bateman J, Clarke S. Sudden death in asthma. Thorax. 1979;34:40–4.
6. Macdonald JB, Seaton A, Williams DA. Asthma deaths in Cardiff 1963–74: 90
deaths outside hospital. Br Med J. 1976;1:1493–5.
7. Macdonald JB, Macdonald ET, Seaton A, Williams DA. Asthma deaths in
Cardiff 1963–74: 53 deaths in hospital. Br Med J. 1976;2:721–3.
8. Hetzel MR, Clarke TJH, Branthwaite MA. Asthma: analysis of sudden deaths
and ventilatory arrests in hospital. Br Med J. 1977;1:808–11.
9. Somerville M, Williams EM, Pearson MG. Asthma deaths in Mersey region
1989–1990. J Pub Health Med. 1995;17:397–403.
10. Global Initiative for Asthma (GINA). The global strategy for asthma
management and prevention, 2015. Available from http://www.ginasthma.org.
11. O’Hollaren MT, Yunginger JW, Offord KP, et al. Exposure to an aeroallergen
as a possible precipitating factor in respiratory arrest in young patients with
asthma. N Engl J Med. 1991;324(6):359–63.
12. Pulimood T, Corden J, Bryden C, Sharples L, Nasser S. Epidemic asthma and
the role of the fungal mold Alternaria alternata. J Allergy Clin Immunol.
2007;120(3):610–7.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Table 3 Risk factors for asthma death identified from NRAD
Risk Factor
Lack of appropriate action by health care professional or patient during
asthma exacerbation
Excess prescriptions of reliever medication (>12 Short acting beta-
agonist bronchodilator devices in previous 12 months)
Poor adherence with inhaled corticosteroids (<4 in previous 12 months)
Use of long acting beta-agonist bronchodilators without Inhaled
corticosteroids
Hospital admission for asthma in the month before death
Two or more attendances at A&E (ED) in year before death
Failure to phenotype asthma or identify triggers for asthma attacks
Asthma diagnosed in adulthood
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